Distribution of Prothrombotic Risk Factors in Caucasian Patients and Controls
| . | Risk Factors . | Controls (n = 296) . | Patients (n = 148) . | OR (CI) . | χ2 (P Value) . |
|---|---|---|---|---|---|
| Single risk factor | Lp(a) > 30 mg/dL | 14 (4.7%) | 39 (26.4%) | 7.2 (3.8-13.8) | <.0001 |
| FV G1691A (+/−) | 12 (4%) | 30 (20.2%) | 6 (2.97-12.1) | <.0001 | |
| Protein C deficiency | 2 (0.67%) | 9 (6%) | 9.5 (2-44.6) | .001* | |
| PT G20210A | 4 (1.3%) | 9 (6%) | 4.7 (1.4-15.6) | .01* | |
| MTHFR TT 677 genotype | 31 (10.4%) | 35 (23.6%) | 2.64 (1.53-4.5) | <.0001 | |
| Combined risk factors | FV G1691A & Lp(a) > 30 mg/dL | 1 (0.3%) | 11 (7.4%) | 23.6 (3-185) | <.0001* |
| FVG1691A & MTHFR TT677 | — | 5 (3.3%) | — | .004* | |
| Combinations (total) | FV G1691A & Lp(a) > 30 mg/dL or MTHFR TT677 | 1 (0.3%) | 16 (10.8%) | 35.75 (4.7-272) | <.0001* |
| . | Risk Factors . | Controls (n = 296) . | Patients (n = 148) . | OR (CI) . | χ2 (P Value) . |
|---|---|---|---|---|---|
| Single risk factor | Lp(a) > 30 mg/dL | 14 (4.7%) | 39 (26.4%) | 7.2 (3.8-13.8) | <.0001 |
| FV G1691A (+/−) | 12 (4%) | 30 (20.2%) | 6 (2.97-12.1) | <.0001 | |
| Protein C deficiency | 2 (0.67%) | 9 (6%) | 9.5 (2-44.6) | .001* | |
| PT G20210A | 4 (1.3%) | 9 (6%) | 4.7 (1.4-15.6) | .01* | |
| MTHFR TT 677 genotype | 31 (10.4%) | 35 (23.6%) | 2.64 (1.53-4.5) | <.0001 | |
| Combined risk factors | FV G1691A & Lp(a) > 30 mg/dL | 1 (0.3%) | 11 (7.4%) | 23.6 (3-185) | <.0001* |
| FVG1691A & MTHFR TT677 | — | 5 (3.3%) | — | .004* | |
| Combinations (total) | FV G1691A & Lp(a) > 30 mg/dL or MTHFR TT677 | 1 (0.3%) | 16 (10.8%) | 35.75 (4.7-272) | <.0001* |
Fischer’s exact test.